Vascular smooth muscle actin is reduced in Alzheimer disease brain: A quantitative analysis

Journal of Neuropathology and Experimental Neurology

Volumn 63, Issue 7, 2004, Pages 735-741

  Ervin, John F ^b   Pannell, Catherine ^b   Szymanski, Mari ^b   Welsh Bohmer, Kathleen ^b   Schmechel, Donald E ^a,b   Hulette, Christine M ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Medicine   (United States)

Author keywords

Alzheimer disease; ApoE; Blood vessels; Image analysis; Smooth muscle actin

Indexed keywords

ACTIN; APOLIPOPROTEIN E4;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ARACHNOID; BRAIN BLOOD VESSEL; COGNITION; CONTROLLED STUDY; DEMENTIA; FEMALE; GENDER; GRAY MATTER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOREACTIVITY; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; VASCULAR SMOOTH MUSCLE; WHITE MATTER;

EID: 3042710057     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/63.7.735     Document Type: Article

References (38)

1. Saunders AM. Apolipoprotein E and Alzheimer disease: An update on genetic and functional analyses. J Neuropathol Exp Neurol 2000;59:751-58
2. Ignatius MJ, Gebicke-Harter PJ, Skene JHP. Expression of apolipoprotein E during nerve degeneration and regeneration. Proc Natl Acad Sci USA 1986;83:1125-29
3. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-23
4. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele α4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72
5. Rebeck GW, Reiter JS, Strickland DK, et al. Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron 1993;11:575-80
6. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased β-peptide deposition in cerebral cortex as a consequence of ApoE genotype in late-onset Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:9649-53
7. Premkumar DRD, Cohen DL, Hedera P, et al. Apolipoprotein E ε4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 1996;148:2083-95
8. McCarron MO, Muir KW, Nicoll JA, et al. Prospective study of apolipoprotein E genotype and functional outcome following ischemic stroke. Arch Neurol 2000;57:1480-84
9. Weir CJ, McCarron MO, Muir KW, et al. Apolipoprotein E genotype, coagulation, and survival following stroke. Neurol 2001;57:1097-1100
10. Macfarlane DP, Nicall JA, Smith C, Graham DI. APOE epsiolon4 allele and amyloid beta-protein deposition in long term survivors of head injury. Neuroreport 1999;10:3945-49
11. Graham DI, Horsburgh K, Nicoll JA, Teasdale GM. Apolipoprotein E and the response of the brain to injury. Acta Neurochir Suppl (Wien) 1999;73:89-92
12. Slooter AJ, Tang MX, van Duijn CM, et al. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. JAMA 1997;277:818-21
13. Zhang WW, Badonic T, Hoog A, et al. Structural and vasoactive factors influencing intracerebral arterioles in cases of vascular dementia and other cerebrovascular disease: A review. Dementia 1994;5:153-62
14. Zhang WW, Lempessi H, Olsson Y. Amyloid angiopathy of the human brain: Immunohistochemical studies using markers for components of extracellular matrix, smooth muscle actin and endothelial cells. Acta Neuropathol 1998;96:558-63
15. Cumming AM, Robertson FW. Polymorphism at the apolipoprotein-E locus in relation to risk of coronary disease. Clin Genet 1984;25:310-13
16. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1-21
17. Van Brockmeyer FM, Mamotte CD. Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet 1992;340:879-80
18. Stengard JH, Zerba KE, Pekkanen J, et al. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 1995;91:265-69
19. Buee L, Delacourte A, Hof PR. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and relating dementing disorders. Acta Neuropathol 1994;87:469-80
20. Buee I, Hof PR, Delacourte A. Brain microvascular changes in Alzheimer's disease and other dementias. Ann NY Acad Sci 1997;826:7-24
21. Strittmatter WJ, Saunders AM, Schmechel DE, et al. Apolipoprotein E: High avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:1977-81
22. Einstein G, Patel V, Bautista P, et al. Intraneuronal ApoE in human visual cortical areas reflects the staging of Alzheimer's disease pathology. J Neuropathol Exp Neurol 1998;57:1190-1201
23. st International Congress of Vascular Dementia. Bologna, Italy: Monduzzi Editore, 1999:45-49
24. Hulette CM, Welsh-Bohmer KA, Crain B, Szymanski MH, Sinclaire NO, Roses AD. Rapid brain autopsy: The Bryan Alzheimer's Disease Research Center experience. Arch Pathol Lab Med 1997;121:615-18
25. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997;56:1095-97
26. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
27. Hulette CM, Welsh-Bohmer KA, Murray MG, et al. Neuropathological and neuropsychological changes in "normal" aging. Evidence for preclinical Alzheimer's disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998;57:1168-74
28. th International Conference on Alzheimer's Disease and Related Disorders. London: John Wiley & Sons, 2001
29. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD) Part II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology 1991;41:479-86
30. Boyko OB, Alston SR, Fuller GN, Hulette CM, Johnson GA, Burger PC. Utility of postmortem magnetic resonance imaging in clinical neuropathology. Arch Pathol Lab Med 1994;118:219-25
31. Vinters HV, Wang ZZ, Lenard-Secor D. Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol 1996;6:179-95
32. Wisniewski HM, Wegiel J. β-amyloid formation by myocytes of leptomeningeal vessels. Acta Neuropathol 1994;87:233-41
33. Wisniewski T, Frangione B. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992;135:235-38
34. Coria F, Rubio I. Cerebral amyloid angiopathies. Neuropathol App Neurobiol 1996;22:216-27
35. Van Nostrand WE, Davis-Salinas I, Saporito-Irwin SM. Amyloid β-protein induces the cerebrovascular cellular pathology of Alzheimer's disease and related disorders. Ann NY Acad Sci 1996;777:297-302
36. Fullerton SM, Strittmatter WJ, Matthew WD. Peripheral sensory nerve defects in apolipoprotein E knockout mice. Exp Neurol 1998;153:156-63
37. Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD. Impairment of the blood-nerve and blood-brain barriers in apolipoprotein E knockout mice. Exp Neurol 2001;169:13-22
38. Preston SD, Steart PV, Wilkinson SA, Nicoll JAR, Weller RO. Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: Defining the perivascular route for the elimination of amyloid β from the human brain. Neuropathol App Neurobiol 2003:106-17